Derivation of point of departure (PoD) estimates in genetic toxicology studies and their potential applications in risk assessment.
about
Causes of genome instability: the effect of low dose chemical exposures in modern societyGenetic toxicity assessment of engineered nanoparticles using a 3D in vitro skin model (EpiDerm™)Comparison of in vitro and in vivo clastogenic potency based on benchmark dose analysis of flow cytometric micronucleus data.The use of dose-response data in a margin of exposure approach to carcinogenic risk assessment for genotoxic chemicals in food.Evaluation of the automated MicroFlow® and Metafer™ platforms for high-throughput micronucleus scoring and dose response analysis in human lymphoblastoid TK6 cells.MutAIT: an online genetic toxicology data portal and analysis tools.Correlation of In Vivo Versus In Vitro Benchmark Doses (BMDs) Derived From Micronucleus Test Data: A Proof of Concept StudyKinetic Modeling Reveals the Roles of Reactive Oxygen Species Scavenging and DNA Repair Processes in Shaping the Dose-Response Curve of KBrO₃-Induced DNA Damage.Opportunities to integrate new approaches in genetic toxicology: an ILSI-HESI workshop report.Incorporation of metabolic activation potentiates cyclophosphamide-induced DNA damage response in isogenic DT40 mutant cellsContributions of DNA repair and damage response pathways to the non-linear genotoxic responses of alkylating agents.Genotoxicity of flubendazole and its metabolites in vitro and the impact of a new formulation on in vivo aneugenicity.Transcriptomic responses in the oral cavity of F344 rats and B6C3F1 mice following exposure to Cr(VI): Implications for risk assessment.The clastogenicity of 4NQO is cell-type dependent and linked to cytotoxicity, length of exposure and p53 proficiency.An appraisal of critical effect sizes for the benchmark dose approach to assess dose-response relationships in genetic toxicology.Development of an in vitro PIG-A gene mutation assay in human cells.Pharmacology-based toxicity assessment: towards quantitative risk prediction in humans.Empirical analysis of BMD metrics in genetic toxicology part I: in vitro analyses to provide robust potency rankings and support MOA determinations.Setting Occupational Exposure Limits for Genotoxic Substances in the Pharmaceutical Industry.Regulatory requirements for genotoxicity assessment of plant protection product active ingredients, impurities, and metabolites.International regulatory requirements for genotoxicity testing for pharmaceuticals used in human medicine, and their impurities and metabolites.Comparison of integrated genotoxicity endpoints in rats after acute and subchronic oral doses of 4-nitroquinoline-1-oxide.Next generation testing strategy for assessment of genomic damage: A conceptual framework and considerations.Dose-response relationship of temozolomide, determined by the Pig-a, comet, and micronucleus assay.Global regulatory requirements for mutagenicity assessment in the registration of industrial chemicals.Genetic toxicology at the crossroads-from qualitative hazard evaluation to quantitative risk assessment.Empirical analysis of BMD metrics in genetic toxicology part II: in vivo potency comparisons to promote reductions in the use of experimental animals for genetic toxicity assessment.A proposal for a novel rationale for critical effect size in dose-response analysis based on a multi-endpoint in vivo study with methyl methanesulfonate.Estimating the carcinogenic potency of chemicals from the in vivo micronucleus test.Dose-Response for Multiple Biomarkers of Exposure and Genotoxic Effect Following Repeated Treatment of Rats with the Alkylating Agents, MMS and MNU.Quantitative analysis of the relative mutagenicity of five chemical constituents of tobacco smoke in the mouse lymphoma assay.Sublinear response in lacZ mutant frequency of Muta™ Mouse spermatogonial stem cells after low dose subchronic exposure to N-ethyl-N-nitrosourea.Benzo(a)pyrene Is Mutagenic in Mouse Spermatogonial Stem Cells and Dividing Spermatogonia.Comparing BMD-derived genotoxic potency estimations across variants of the transgenic rodent gene mutation assay.Benchmark dose analyses of multiple genetic toxicity endpoints permit robust, cross-tissue comparisons of MutaMouse responses to orally delivered benzo[a]pyrene.Quantitative differentiation of whole smoke solution-induced mutagenicity in the mouse lymphoma assay.In Vitro Genotoxicity Testing: Significance and Use in Environmental Monitoring.Evaluation of the in vivo mutagenicity of isopropyl methanesulfonate in acute and 28-day studies.An integrative test strategy for cancer hazard identification.New approaches to advance the use of genetic toxicology analyses for human health risk assessment
P2860
Q28388277-2DCCBF47-F602-485A-8BB3-FB019913A350Q28389006-5D96B30C-2429-413F-9D3A-220E95652D55Q30967038-770F4FFD-7060-46F4-B38D-8247311F4445Q30989117-902CE354-2E5E-4275-BA00-9B6F53608FBDQ33849452-CD7450BA-9FD3-4234-AA92-24668A2DDDABQ35712638-2D3399CE-7980-4BDA-9561-D43640ECF52DQ35800710-663A6B11-4AB7-475A-A072-CA680FEB2AB4Q36089306-81A0F3DE-F61D-40A0-9712-CE90E2AF74FFQ36191404-8704936E-E773-46FE-B88B-3086B8134A11Q36492435-ED6C8AA9-A730-49A1-8101-BF8D56A7A190Q36759955-5AA37327-BD5A-4A20-9D65-C64025470993Q36823829-3B87F367-13C1-4F09-9F34-EB9E357D8353Q37561128-FE004740-FE14-4231-BDF5-FC146818CE7DQ38332062-7331E2FC-506A-41EF-8D03-2A9D0088AE2EQ38629352-5D2822F2-F726-4CB0-8890-6E6E2DFFEA86Q38722763-BC3E25FE-6638-4773-9523-6CD34FD39488Q38771635-691EAF7A-A52C-4AC1-8385-8139E52A83CFQ38810274-2101E231-EA3C-4D53-ABAB-8DDE3A21843BQ38840499-042C4550-67E9-4CC7-A76C-1C024876AFA9Q38886272-BD12EB21-641F-41BF-81F4-983955F425D3Q38904138-51E7C57B-8A6B-4397-8AC0-AB98085D3DF5Q38960044-58FA6072-7609-4712-8442-13FF71A9FB78Q38960123-E21F0F56-BD1A-4B4C-91DC-90E3950ABF50Q38961317-0B32EE42-B489-4682-9F2E-D3F02680C3AAQ39329616-582EF59D-6C61-4CA0-9EEA-6F5B5DF034FBQ39900603-0DE83E3F-23CE-4F12-B3F8-27D090BC8EE3Q39914607-2890DF81-945B-4756-A82E-2274D029CE38Q40293697-74032614-FCA8-4CC1-AD54-D6CFE4C22748Q40748973-725741B2-DC4E-434E-8D92-101EBA5C9325Q40872489-0939F313-E95A-4FC7-813A-DD1BF51F3800Q40910525-71DA35AE-6247-4C80-ADA9-3CEC19FC72C0Q41566029-7B0709DE-033C-4A67-898A-A7A81441742EQ42101489-40F0A3DD-820E-4C27-A21E-FB3DC4072639Q46262205-BE1E0803-768A-4B43-AA6F-4725863F2F03Q47410180-19ED7516-2875-4983-BCD9-396846A0E0ACQ47627704-45A68C1A-D7B0-494C-9BB4-BCB24E7CFB6FQ49961867-5259DDEB-DA2F-45F4-B9F0-FC8684CB1EFCQ50460175-A89B906C-3A0A-437C-BD73-B2D2E110D0D3Q50856445-FFDBF79A-F8B3-4595-B1E5-7A43ACA82C0EQ57555089-5FDECF99-7D2A-41A8-A5D2-4A254C4B74EB
P2860
Derivation of point of departure (PoD) estimates in genetic toxicology studies and their potential applications in risk assessment.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年学术文章
@wuu
2014年学术文章
@zh
2014年学术文章
@zh-cn
2014年学术文章
@zh-hans
2014年学术文章
@zh-my
2014年学术文章
@zh-sg
2014年學術文章
@yue
2014年學術文章
@zh-hant
name
Derivation of point of departu ...... plications in risk assessment.
@en
Derivation of point of departure
@nl
type
label
Derivation of point of departu ...... plications in risk assessment.
@en
Derivation of point of departure
@nl
prefLabel
Derivation of point of departu ...... plications in risk assessment.
@en
Derivation of point of departure
@nl
P2093
P2860
P356
P1476
Derivation of point of departu ...... pplications in risk assessment
@en
P2093
B B Gollapudi
C M Thompson
D P Lovell
J T MacGregor
J van Benthem
K L Dearfield
P2860
P304
P356
10.1002/EM.21870
P577
2014-05-06T00:00:00Z